Today kicks off #EHA2024. Actinium is looking forward to presenting results from the Phase 3 SIERRA trial of Iomab-B this weekend that showed long-term efficacy results in older patients receiving an Iomab-B led #BMT.
Actinium Pharmaceuticals, Inc.’s Post
More Relevant Posts
-
Great sharing on Results of NETTER-2 , Lu-177 dotatate for Advanced GEP NET. Nouzha WiNMI leader,Group Expert of WiN Global EANM _WE Vp #WiNGlobal,#WiNMI,#WiN for peace,#WiN YG,#WiN Africa,#WiN IAEA,#WiN France,#WiN Europe,#AMMN ,#SNMMI,#PSNM,#AI,#Nuclear Medicine,#Oncology,#Molecular Imaging,#Myocardial imaging,#ASCO,#EANM,#EANM_WE,#EANM_WE, #WARMTH, #alpha Therapy, #beta Nuclear Medicine therapyVp,#Oncidium,#ESMIT,#SFMN,#UCLA,#EJNMMI,#Americanoncologyinstitute,#Urology,#Prostate,#TNE,#WiA,#Gliomas,#Lymphomas,#Burkitt,#PRRT,#211At,#Neurology,#Alzheimer,#Thyroid cancer
The results of NETTER-2 Trial showed what we already expected from the treatment with Lu-177 dotatate. PRRT significantly improved progression-free survival in patients with high-grade GEP NETS. https://lnkd.in/dt6tgJ2h
To view or add a comment, sign in
-
DCRI's Jennifer Rymer and Schuyler Jones, along with former DCRI member Sunil Rao, joined their colleagues at #ACC24 this morning for a deep dive into the ACS toolbox, where they examined guidelines, proven and potential therapies, and opportunities to tailor approaches to each patient's unique characteristics and needs. Jones took the opportunity to reinforce GDMT adherence after ACS and noted 30% of patients still don't receive the Big 5 (aspirin, beta blockers, ACE inhibitors, statins, P2Y12 inhibitors). #clinicaltrials #clinicalresearch #hearthealth #heartdisease
To view or add a comment, sign in
-
https://lnkd.in/dBPbnT9Q #BTKi have changed the face of CLL management now further cementing the notion that targeted therapies are the way forward in #CLL , the marriage between #BTKi and #BCL2 targeting has marked the final chapter in the book of chem-free & infusion-free treatment, rendering this incurable disease into the realm of potential cure and outfacing the most potent chemoimmunotherapy regimen, while providing the at home convenience to patients and the healthcare system #Just_Bring_It #fast_forward #patients_first
UK NCRI FLAIR trial: ibrutinib + venetoclax with MRD-directed duration of treatment in CLL
https://www.youtube.com/
To view or add a comment, sign in
-
Join Wendy Strait at #ITIUSA2024 for a discussion on how adding multi-cancer early detection with the Galleri test can make a meaningful impact in your clients’ lives. See Important Safety Information: http://bit.ly/33m8pFa #LifeInsurance #InsurtechInsights #MCED
To view or add a comment, sign in
-
Check out our latest article summarizing the post-hoc analyses of the phase II PAISLEY trial in patients with SLE treated with deucravacitinib, presented at #ACR23. 👉 https://loom.ly/Imu0Mlo #MedEd #lupus
To view or add a comment, sign in
-
IV tenecteplase is as safe and effective as IV alteplase in this substudy of 520 stroke patients with LVO from the Alteplase compared to Tenecteplase (AcT) trial. https://ja.ma/45nS6Go
To view or add a comment, sign in
-
What impact does treatment with ropeginterferon alfa-2b have on event-free survival in patients with polycythemia vera? Read our latest article on the final data from PROUD-PV and its extension trial CONTINUATION-PV to find out! 👉 https://loom.ly/FA80bes #MPN #MPNsm
To view or add a comment, sign in
-
🫀 Treating In-Stent Restenosis 🫀 13 October, 17:05 - 17:50 CEST ✅ Explore thrombosis, in-stent stenosis, and IVUS. ✅ Learn Jetstream's effectiveness, safe in-stent techniques, and IVUS benefits. ✅ How do patients reach the Lab in the Acute Phase? ✅ Why and how to treat patients with Acute DVT using AngioJet™ Register now ➡️ https://ow.ly/z28650PUy3z This breakout is supported by Boston Scientific. #VIO2023
To view or add a comment, sign in
-
Gain insight into your AAV vector to improve safety and efficiency. Join this webinar as our experts discuss the cell-based assays that can be used to establish product safety and infectivity along with the regulatory expectations for determining AAV vector titer and absence of replication competent AAV.
To view or add a comment, sign in
-
Gain insight into your AAV vector to improve safety and efficiency. Join this webinar as our experts discuss the cell-based assays that can be used to establish product safety and infectivity along with the regulatory expectations for determining AAV vector titer and absence of replication competent AAV.
Take the reins of your AAV-based therapy: Ensuring safety with cell-based analytical testing
event.on24.com
To view or add a comment, sign in
12,797 followers